Circulating s-Endoglin concentrations in non-obese patients with gestational diabetes mellitus

References

• ACOG. 2013. Practice Bulletin No. 137: gestational diabetes mellitus. Obstetrics and Gynecology 122:406–416.
   PubMedGoogle Scholar
• Alqudah A, Eastwood KA, Djurdja Jerotic D, Naomi Todd N, Hoch D, and, et all. 2021. FKBPL and SIRT-1 are downregulated by diabetes in pregnancy impacting on angiogenesis and endothelial function. Frontiers In Endocrinology. 12:650328.
   PubMed Web of Science ®Google Scholar
• Anık A, Çelik E, Çevik O, Unüvar T, Anık A. 2020. The relation of serum endocan and soluble endoglin levels with metabolic control in children and adolescents with type 1 diabetes mellitus. Journal of Pediatric Endocrinology and Metabolism 33:1013–1018.
   Web of Science ®Google Scholar
• Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, Recio Rodriquez JI, Sanchez-Rodriguez A, Lopez-Novoa JM, Martinez-Salgado C. 2010. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC 20:86.
   Google Scholar
• Bo S, Valpreda S, Menato G, Bardelli C, Botto C, Gambino R, et al. 2007. Should we consider gestational diabetes a vascular risk factor? Atherosclerosis 194:e72–e79.
   PubMed Web of Science ®Google Scholar
• Chang SC, Vivian WC. 2013. Hyperglycemia induces altered expressions of angiogenesis associated molecules in the trophoblast. Evidence-Based Complementary and Alternative Medicine: eCAM 2013:457971.
   PubMed Web of Science ®Google Scholar
• Cohen AL, Wenger JB, James-Todd T, Lamparello BM, Halprin E, Serdy S, et al. 2014. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertension in Pregnancy 33:81–92.
   PubMed Web of Science ®Google Scholar
• Di Marco GS, Alam A, Dol F, Corvol P, Gasc J-M, Larger E. 2008. Larger E angiogenesis and diabetes: different responses to pro-angiogenic factors in the chorioallantoic membrane assay. Molecular Medicine (Cambridge, Mass.) 14:705–714.
   PubMed Web of Science ®Google Scholar
• Drela E, Kulwas A, Ruszkowska B, Rość D. 2013. The diversity of angiogenesis in diabetic vascular complications. Folia Medica Copernicana 1:53–57.
   Google Scholar
• Emeksiz HC, Bideci A, Damar Ç, Derinkuyu B, Çelik N, Döğer E, et al. 2016. Soluble endoglin level increase occurs prior to development of subclinical structural vascular alterations in diabetic adolescents. Journal of Clinical Research in Pediatric Endocrinology 8:313–320. 1
   PubMed Web of Science ®Google Scholar
• Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, et al. 2008. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. The Journal of Maternal-Fetal & Neonatal Medicine 21:279–287.
   PubMed Web of Science ®Google Scholar
• Fang P, Bo P, Shi M, Yu M, Zhang Z. 2013. Circulating galanin levels are increased in patients with gestational diabetes mellitus. Clinical Biochemistry. 46:831–833.
   PubMed Web of Science ®Google Scholar
• Huynh J, Dawson D, Roberts D, Bentley-Lewis R. 2015. A systematic review of placental pathology in maternal diabetes mellitus. Placenta 36:101–114.
   PubMed Web of Science ®Google Scholar
• Ikemoto T, Hojo Y, Kondo H, Takahashi N, Hirose M, Nishimura Y, et al. 2012. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels 27:344–351.
   PubMed Web of Science ®Google Scholar
• Kim SK, Romero R, Savasan ZA, Xu Y, Dong Z, Lee CD, et al. 2013. Endoglin in amniotic fluid as a risk factor for the subsequent development of bronchopulmonary dysplasia. American Journal of Reproductive Immunology 69:105–123.
   PubMed Web of Science ®Google Scholar
• Kopczyńska E, Dancewicz M, Kowalewski J, Makarewicz R, Kardymowicz H, Kaczmarczyk A, Tyrakowski T. 2012. Influence of surgical resection on plasma endoglin (CD105) level in non-small cell lung cancer patients. Experimental Oncology 34:53–56.
   PubMedGoogle Scholar
• Lappas M. 2014. Markers of endothelial cell dysfunction are increased in human omental adipose tissue from women with pre-existing maternal obesity and gestational diabetes. Metabolism: Clinical and Experimental 63:860–873.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. 2006. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New England Journal of Medicine 355:992–1005.
   PubMed Web of Science ®Google Scholar
• Lim JH, Kim SY, Park SY, Lee MH, Yang JH, Kim MY, et al. 2009. Soluble endoglin and transforming growth factor-β1 in women who subsequently developed preeclampsia. Prenatal Diagnosis 29:471–476.
   PubMed Web of Science ®Google Scholar
• López-Novoa JM, Bernabeu C. 2010. The physiological role of endoglin in the cardiovascular system. The American Journal of Physiology-Heart and Circulatory Physiology 299:H 959–H974.
   Web of Science ®Google Scholar
• Matarese G, La CA, Sanna V, Lord GM, Lechler RI, Fontana S, Zappacosta S. 2002. Balancing susceptibility to infection and autoimmunity: a role for leptin? Trends in Immunology 23:182–187.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man . Diabetologia 28:412–419.
   PubMed Web of Science ®Google Scholar
• Mijal RS, Holzman CB, Rana S, Karumanchi SA, Wang J, Sikorskii A. 2011. Midpregnancy levels of angiogenic markers in relation to maternal characteristics . American Journal of Obstetrics and Gynecology 204:244.e1–244.12.
   PubMed Web of Science ®Google Scholar
• Radikova Z. 2003. Assessment of insulin sensitivity/resistance in epidemiological studies. Endocrine Regulations 37:189–194.
   PubMedGoogle Scholar
• Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. 2008. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. The Journal of Maternal-Fetal & Neonatal Medicine 21:9–23.
   PubMed Web of Science ®Google Scholar
• Sezer SD, Küçük M, Yenisey Ç, Yüksel H, Odabaşı AR, Türkmen MK, et al. 2012. Comparison of angiogenic and antiangiogenic factors in maternal and umbilical cord blood in early- and late-onset pre-eclampsia. Gynecological Endocrinology 28:628–632.
   PubMed Web of Science ®Google Scholar
• Sezer SD, Küçük M, Yüksel H. 2012. Angiogenic and anti-angiogenic factors in the etiology of pre-eclampsia: review. Türkiye Klinikleri Jinekoloji Obstetrik Dergisi. Turkiye Klinikleri J Gynecol Obst 22:42–47.
   Google Scholar
• Smith GC, Wear H. 2009. The perinatal implications of angiogenic factors. Curr Opin Obstet Gynecol 21:111–116.
   PubMed Web of Science ®Google Scholar
• Yu Y, Jenkins AJ, Nankervis AJ, Hanssen KF, Scholz H, Henriksen T, et al. 2009. Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women. Diabetologia 52:160–168.
   PubMed Web of Science ®Google Scholar